Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness

Beth Woods, Mark Sculpher, Matthew R. Sydes et al.|European Urology Oncology|2018

Cited by 27